HC Wainwright Has Optimistic Outlook of MIRM FY2026 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a research note issued on Thursday, August 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.37) for the year, up from their prior forecast of ($3.78). HC Wainwright currently has a “Buy” rating and a $140.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($4.42) per share.

Several other equities analysts have also recently issued reports on the stock. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday. Robert W. Baird set a $123.00 target price on Mirum Pharmaceuticals in a research note on Thursday. Citizens Jmp dropped their price objective on Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating on the stock in a report on Thursday, August 6th. Stifel Nicolaus set a $136.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $137.33.

Mirum Pharmaceuticals Trading Down 1.9%

NASDAQ:MIRM opened at $98.70 on Tuesday. Mirum Pharmaceuticals has a 12-month low of $58.48 and a 12-month high of $130.00. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. The stock’s 50 day simple moving average is $110.38 and its 200-day simple moving average is $101.91. The firm has a market cap of $6.41 billion, a P/E ratio of -6.78 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. During the same period in the prior year, the company earned ($0.12) earnings per share. The firm’s revenue was up 37.9% on a year-over-year basis.

Insider Activity

In related news, SVP Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total transaction of $326,520.00. Following the transaction, the senior vice president owned 3,114 shares in the company, valued at approximately $373,680. The trade was a 46.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the sale, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 67,155 shares of company stock valued at $7,185,662. Company insiders own 8.32% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of MIRM. Comerica Bank grew its position in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Mirum Pharmaceuticals by 7.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after purchasing an additional 1,720 shares in the last quarter. Caxton Associates LLP purchased a new stake in Mirum Pharmaceuticals during the 1st quarter worth $217,000. Finally, Empowered Funds LLC lifted its holdings in Mirum Pharmaceuticals by 15.4% in the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after buying an additional 5,120 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.